The global burden of gallbladder cancer is strikingly uneven. According to GLOBOCAN 2022 data cited in the review, the disease accounted for 122,491 new cases and 89,055 deaths worldwide, with Asia shouldering roughly 71 percent of incidence and 75 percent of mortality. China and India alone contribute more than a quarter and nearly a fifth of global cases, respectively. Within India, incidence in northern and northeastern states such as Bihar, Uttar Pradesh, Assam, Odisha, and West Bengal is nearly seven times higher than in the south, matching rates seen in the world’s highest-prevalence regions of South America and North Africa. Women are two to six times more susceptible than men, and risk factors including gallstones, chronic infections with Salmonella typhi and Helicobacter pylori, obesity, and exposures to aflatoxins and arsenic compound a genetic predisposition to the disease.

A central and increasingly appreciated driver of this carcinogenesis is microbial dysbiosis within the biliary ecosystem. Enrichment of bacterial taxa such as Enterobacteriaceae, Streptococcus, and Helicobacter species shifts bile acid metabolism toward secondary bile acids like deoxycholic acid, which inflict detergent-like DNA damage and activate pro-survival signaling through EGFR and Wnt/beta-catenin pathways. Bacterial genotoxins, including cytolethal distending toxin and colibactin, further destabilize the genome, and chronic inflammation driven by reactive oxygen species contributes directly to TP53 mutations, the most frequent alteration in gallbladder cancer. The review’s authors emphasize that dysbiosis is not a passive bystander but an active sculptor of the tumor microenvironment, accelerating both the generation and selection of oncogenic mutations as chronic cholecystitis progresses through dysplasia to invasive carcinoma.

To organize this complexity, the researchers mined The Cancer Genome Atlas and the COSMIC database to identify twelve recurrently mutated genes: TP53, SMAD4, PIK3CA, CDKN2A, ARID1A, ARID2, KRAS, ELF3, ERBB3, ERBB2, STK11, and CTNNB1. TP53 dominates the landscape, mutated in up to 70 percent of cases, with TCGA reporting 58.6 percent and COSMIC 44 percent. Most are missense mutations in the DNA-binding domain spanning exons 5 to 8, which not only abolish the protein’s tumor-suppressive transcriptional activity but also confer gain-of-function properties. Mutant p53 accumulates to high levels in invasive tumors while being virtually absent in normal gallbladder epithelium, marking it as an early event in malignant transformation and a potential diagnostic marker.

The remaining genes map onto a web of interconnected pathways. SMAD4, altered in roughly 12 to 21 percent of tumors, cripples TGF-beta signaling, with mutations concentrated in the MH2 domain that mediates complex formation with receptor-regulated SMADs. PIK3CA, mutated in about 7 to 10 percent of cases, encodes the p110-alpha catalytic subunit of PI3K; hotspot mutations E542K, E545K, and H1047R constitutively activate the PI3K/AKT survival axis. CDKN2A, altered in roughly 9 to 10 percent of tumors, disables two cell-cycle sentinels: p16, which blocks cyclin D-CDK4/6-driven phosphorylation of the retinoblastoma protein, and p14, which stabilizes p53 by sequestering MDM2. Chromatin remodelers ARID1A and ARID2, mutated in about 20 percent and 8 percent of tumors respectively, destabilize the SWI/SNF complex, impairing DNA damage repair and gene regulation. Notably, ARID1A deficiency in gallbladder cancer drives overexpression of PD-L1 and impairs tumor-infiltrating lymphocytes, promoting immune evasion and worse outcomes.

On the oncogene side, KRAS mutations, found in 7 to 12 percent of cases, lock the small GTPase in its active GTP-bound state, most often through codon 12 substitutions such as G12D and G12V, fueling persistent MAPK and PI3K/AKT signaling. The receptor tyrosine kinases ERBB2 and ERBB3, each mutated in 5 to 8 percent of tumors, heterodimerize to hyperactivate PI3K/AKT; experimental work has shown that ERBB2/ERBB3 mutants robustly drive gallbladder cancer progression in vivo. CTNNB1 mutations in exon 3, including S45 and S37 variants, prevent phosphorylation-dependent degradation of beta-catenin, allowing constitutive Wnt signaling. Perhaps most intriguing is ELF3, which acts as a tumor suppressor in gallbladder cancer: its loss upregulates epiregulin, activating EGFR/mTORC1 signaling and driving epithelial-to-mesenchymal transition, invasion, and advanced tumor stage.

What elevates this review beyond a catalog of mutations is its pathway-level synthesis, drawing on how the same alterations behave in better-studied cancers. Mutant p53 in breast and colon cancers suppresses onco-protective microRNAs, hyperactivates chromatin modifiers, and confers cisplatin resistance, suggesting similar mechanisms may operate in gallbladder tumors. SMAD4’s R361C mutation in colorectal cancer disrupts oligomerization and aberrantly activates Wnt/beta-catenin signaling instead of apoptosis. A protein-protein interaction network analysis using STRING and CytoHubba identified ERBB2 and KRAS as central hub genes in gallbladder cancer, and the authors point to pancreatic cancer evidence that pharmacological co-targeting of these two drivers with the ERBB2 inhibitor neratinib and the KRAS G12C inhibitor ARS-1620 produced profound growth suppression in xenograft models, a strategy they argue could be adapted for gallbladder tumors harboring co-occurring mutations.

The therapeutic implications are concrete. Current first-line treatment combines gemcitabine and cisplatin with immunotherapy: the phase 3 TOPAZ-1 and KEYNOTE-966 trials established that adding durvalumab or pembrolizumab to chemotherapy improves overall survival in biliary tract cancers. But low PD-1 or CTLA-4 expression excludes many patients from benefit, underscoring the need for molecularly matched options. The review catalogs drugs already approved or in trials for other cancers that target the same mutated proteins: p53 reactivators such as APR-246 and arsenic trioxide; PI3K-alpha inhibitors alpelisib and the mutant-selective RLY-2608; KRAS G12C inhibitors sotorasib and adagrasib alongside emerging G12D agents; CDK4/6 inhibitors for CDKN2A-deficient tumors; the EZH2 inhibitor tazemetostat for ARID1A-mutant cancers; and HER2-directed antibodies, antibody-drug conjugates, and kinase inhibitors. The ongoing SAFIR ABC-10 phase 3 trial is testing matched targeted maintenance therapy in advanced biliary tract cancers, with results pending.

The authors also envision liquid biopsy as a practical bridge to precision care. Because tissue sampling in metastatic gallbladder cancer is invasive and often limited, circulating tumor DNA and bile-derived cell-free DNA profiling could capture spatial and temporal tumor heterogeneity, detecting recurrent TP53 and KRAS mutations and actionable alterations to guide treatment selection. Real-world analyses suggest patients receiving matched targeted therapies, including PARP inhibitors for homologous recombination deficiency and ERBB2-directed agents, survive longer than those on conventional chemotherapy. Even the microbiome may become a therapeutic lever, with precision antibiotics, engineered probiotics, or phage-based antimicrobials potentially reducing genotoxic secondary bile acids and the DNA damage that fuels driver mutations.

Challenges remain substantial. Evidence on STK11 and ERBB3 mutations in gallbladder carcinoma is sparse, and the functional consequences of many alterations have been characterized only in other cancer types. The review’s authors call for multi-omics studies integrating genomics, transcriptomics, and proteomics to build comprehensive mutation-to-phenotype maps, and for rigorous preclinical validation of rational drug combinations in gallbladder cancer organoids and patient-derived xenografts. Still, the message is clear: gallbladder cancer is not a single disease but a collection of molecularly defined subtypes, and decoding the cooperative effects of co-occurring mutations may finally transform treatment from empiric cytotoxic regimens into biomarker-driven therapy tailored to each patient’s tumor, offering hope in a cancer where survival has barely improved for decades.

Subject of Research: Mutational landscape and signaling network crosstalk in gallbladder cancer for precision therapy

Article Title: Mapping Mutations and Signaling Network Interactions to Guide Precision Therapy in Gallbladder Cancer

Article References: Manav, N., Kashyap, A., Malhotra, L., Rajegowda, C., & Prasad, C. P. (2026). Mapping Mutations and Signaling Network Interactions to Guide Precision Therapy in Gallbladder Cancer. Cancer Reports, 9(10), Article e70699. https://doi.org/10.1002/cnr2.70699

Image Credits: AI Generated

DOI: 10.1002/cnr2.70699

Keywords: gallbladder cancer, TP53, KRAS, ERBB2, PIK3CA, precision oncology, mutational landscape, signaling pathways, immunotherapy, liquid biopsy, SWI/SNF, targeted therapy

Biliary tract cancers are not a single disease but a heterogeneous family of tumors that includes intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma and gallbladder cancer. These subtypes differ markedly in their epidemiology, clinical behavior and molecular underpinnings, which is precisely why the research team chose to disaggregate them. Their rationale was grounded in existing biology: several genetic alterations implicated in breast cancer, including HER2 amplification and the pathways connected to BRCA1 and BRCA2, have independently been identified in biliary tract cancers. If shared molecular machinery exists, the authors reasoned, then a history of breast cancer might cluster within one particular biliary subtype rather than across the spectrum. Gallbladder cancer emerged as the prime candidate for such a cluster.

The analysis enrolled 1,687 patients with biliary tract cancer across three centers. A training cohort of 204 patients was treated at San Raffaele in Milan between 2021 and 2023, while an independent validation cohort of 1,483 patients was drawn from the Vall d’Hebron Institute of Oncology in Spain and the Veneto Institute of Oncology in Italy between 2015 and 2023. This two-cohort architecture matters scientifically: any association that reproduces in a validation set is far less likely to be a statistical artifact of a single institution’s referral patterns or record-keeping quirks. The researchers then compared the prevalence of prior breast cancer between gallbladder cancer patients and those with other biliary subtypes within each cohort.

The results were striking in the training cohort. Among patients with gallbladder cancer, 25.7 percent had a documented history of breast cancer, compared with just 3.5 percent of patients with other biliary tract cancer subtypes, an odds ratio of 9.40. In the much larger validation cohort, the association persisted, though at a lower magnitude: previous breast cancer was identified in 5.1 percent of gallbladder cancer patients versus 2.4 percent of those with other subtypes, corresponding to an odds ratio of 2.18. The authors summarized the finding directly, noting that their study demonstrates a higher prevalence of prior breast cancer in patients with gallbladder cancer compared with patients with other biliary tract cancer subtypes across both the training and validation cohorts. The reproducibility across geographically distinct populations lends credibility to the signal, even as the discrepancy in effect size between the cohorts signals that the true magnitude remains uncertain.

Across the two cohorts combined, 58 patients had diagnoses of both breast cancer and biliary tract cancer. In 54 of those patients, or 93.1 percent, breast cancer came first, and the median interval between the two diagnoses was approximately seven years. That temporal sequence is intriguing but not conclusive. The authors are careful to point out that breast cancer is substantially more common than biliary tract cancer and generally occurs at a younger age, so a breast cancer diagnosis preceding a biliary one is, to some extent, exactly what base rates would predict. Sequence alone cannot establish a shared biological cause, and the study was not designed to test causation. What it does establish is that the co-occurrence is not randomly distributed across biliary subtypes, which is a genuinely novel observation.

The most tantalizing thread involves hormones. Among patients for whom breast cancer characteristics were available, most tumors were hormone receptor-positive and classified as luminal A or luminal B, the two subtypes driven by estrogen and progesterone signaling. This observation prompted the researchers to consider whether hormonal pathways might link the two cancers. There is precedent: estrogen and progesterone receptors have previously been described in gallbladder lesions, and estrogen-related signaling has been implicated experimentally in gallbladder cancer biology. The gallbladder, after all, is an organ exposed to circulating steroid hormones, and laboratory models have suggested that estrogen signaling can influence proliferation in gallbladder tissue. Still, the authors emphasize that the evidence for a hormonal connection remains limited and inconclusive, and the current study did not include the kind of receptor profiling in gallbladder tumors that would directly test the hypothesis.

The team also probed molecular similarities using genomic profiling, though only for a relatively small subgroup of gallbladder cancers. Alterations involving HER2, MDM2, CDKN2A, MTAP, ARID1A and CDKN2B occurred more frequently among patients with a history of breast cancer, while STK11 alterations were found exclusively among those without such a history. Several of these genes are familiar players in oncology: HER2 is a canonical breast cancer driver also actionable in a subset of biliary cancers, CDKN2A and CDKN2B govern cell-cycle checkpoints, and ARID1A is a chromatin-remodeling gene mutated across many tumor types. Yet none of the differences reached statistical significance, and the authors are explicit that the genomic findings should be considered exploratory rather than evidence of a shared molecular mechanism. The sample sizes simply were not sufficient to detect anything but very large effects.

A third hypothesis concerns inherited susceptibility. Germline alterations in genes such as BRCA1, BRCA2, BAP1 and STK11 are associated with hereditary cancer syndromes, and BRCA1 and BRCA2 are well established as drivers of inherited breast cancer risk. If a subset of patients carried germline variants predisposing to both malignancies, that could explain why breast cancer history clusters among gallbladder cancer patients. Unfortunately, germline testing was not available in the current study, so whether inherited genetic factors contribute to the observed association remains an open question. This gap is significant, because it means the study cannot distinguish between a shared environmental or hormonal exposure, common germline genetics, and the possibility that treatment or surveillance patterns for breast cancer survivors merely increase the likelihood that an incidental gallbladder tumor is detected.

The study’s limitations deserve emphasis. Its retrospective design could introduce inaccuracies in medical histories, and biological information was incomplete for some breast cancer cases. Genomic profiling was not performed uniformly across biliary tract cancer samples, the molecular analyses involved small numbers of patients, and germline testing was unavailable. The markedly different frequencies of prior breast cancer observed in the training and validation cohorts, 25.7 percent versus 5.1 percent among gallbladder cancer patients, underscore how much additional work is needed before the magnitude of the association can be pinned down. Referral patterns, screening intensity and differences in local practice could all contribute to that variation, and none can be excluded with retrospective data.

Nevertheless, the core finding is reproducible and clinically provocative: a history of breast cancer is overrepresented among gallbladder cancer patients relative to other biliary tract cancer patients in two independent cohorts. Hormonal signaling, inherited susceptibility and overlapping molecular pathways are all plausible explanations, but none has yet been established. The authors argue that future studies should invert the analytical direction, starting with breast cancer populations and investigating their subsequent risk of biliary tract cancer, particularly gallbladder cancer. Such forward-looking cohort designs could determine whether breast cancer survivors genuinely face an elevated risk and whether the association might eventually inform risk stratification or long-term surveillance strategies. For now, the study stands as a well-powered observational signal, a biological puzzle with three candidate mechanisms, and a clear roadmap for the prospective research that must follow before any change to clinical practice could be justified.

Subject of Research: Association between prior breast cancer and gallbladder cancer prevalence among biliary tract cancer subtypes

Article Title: Prior breast cancer linked to higher prevalence of gallbladder cancer among biliary tract cancers

Article References: Prior breast cancer linked to higher prevalence of gallbladder cancer among biliary tract cancers. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: gallbladder cancer, breast cancer, biliary tract cancer, cholangiocarcinoma, hormone receptors, HER2, BRCA1, BRCA2, genomic profiling, retrospective cohort study, cancer epidemiology, Oncoscience

Gallbladder carcinoma is uncommon, but it is among the most aggressive cancers of the biliary tract. Many patients have few specific symptoms during its early stages, and the disease is often discovered only after it has invaded nearby organs, obstructed the bile ducts, or metastasized. Surgery is generally the only treatment with curative potential. Once the tumor involves the hepatic pedicle, major bile ducts, stomach, colon or distant organs, however, an operation may no longer be technically feasible. For unresectable disease, treatment becomes palliative, aiming to relieve obstruction, slow tumor growth and preserve quality of life. Median survival is frequently less than a year in advanced cases.

The patient first sought medical attention in November 2022 with gradually worsening abdominal pain, jaundice, itching, weight loss and a general decline in health. He had no fever and no notable previous medical history. Contrast-enhanced computed tomography showed a swollen gallbladder containing multiple stones. Its wall was mildly and regularly thickened, but radiologists could not identify a distinct mass. Imaging also showed enlargement of the intrahepatic bile ducts upstream from an approximately 18-millimeter narrowing involving the common hepatic duct and the upper common bile duct. The stricture appeared short, smooth and regular, without obvious invasion of the liver, enlarged regional lymph nodes or peritoneal spread.

Magnetic resonance cholangiopancreatography supported the impression of a relatively orderly, tapered obstruction rather than an overtly malignant lesion. There was no irregular “shouldering,” an intraductal mass or conspicuous mural abnormality. Tumor markers, including carcinoembryonic antigen and carbohydrate antigen 19-9, were within normal limits. Yet these markers are imperfect: normal levels do not reliably exclude gallbladder cancer or other biliary tumors. Endoscopic ultrasound and dedicated hepatobiliary ultrasound were not performed at the initial evaluation. In retrospect, that omission may have mattered, because these techniques can provide higher-resolution views of the gallbladder wall and the tissues surrounding the bile ducts, where subtle infiltrative cancers may hide.

The case was therefore initially managed as a likely benign biliary stricture. During endoscopic retrograde cholangiopancreatography, doctors observed regular narrowing and normal-appearing duct lining, with no filling defects. The gallbladder did not fill with contrast. A plastic stent was inserted to drain the bile, and brush cytology from the narrowed duct was negative for malignant cells. The patient was scheduled for elective gallbladder removal. But when surgeons began laparoscopically, the anatomy looked very different from the scans. The gallbladder was distended and had an unusually thick wall. It was tightly fused to the gastric antrum and the hepatic flexure of the colon, making safe dissection difficult.

The operation was converted to an open procedure through a right subcostal incision. Surgeons found a hard, stone-like mass involving the common bile duct, the hepatic pedicle, the lower stomach and the right side of the colon. A separate whitish lesion, about two centimeters wide, was visible in segment III of the liver. The pattern indicated locally advanced gallbladder carcinoma with extension into the extrahepatic bile ducts, and the disease was judged unresectable. Rather than risk a dangerous and incomplete operation, the team abandoned resection and biopsied the liver lesion. Pathological examination identified a well-differentiated adenocarcinoma compatible with biliary origin and confirmed that the liver contained a metastasis.

The patient subsequently received a metal biliary stent and 12 cycles of GEMOX, a chemotherapy combination of gemcitabine and oxaliplatin used for advanced biliary tract cancers. During the early treatment cycles, imaging suggested stable disease, although formal RECIST response criteria were not applied. His condition was monitored every two to three months through clinical examinations, liver-function tests and contrast-enhanced CT scans. Molecular testing for potentially actionable alterations, such as changes involving HER2, FGFR2, IDH1 or NTRK, was not performed because next-generation sequencing was not readily accessible. Treatment consequently followed established chemotherapy practice rather than a genomically selected strategy.

In September 2023, several months after the diagnosis and during the course of systemic therapy, the patient developed a soft, inflamed swelling measuring about five centimeters at the right subcostal surgical scar. He had no laboratory evidence of systemic inflammation, and his kidney, liver and coagulation tests remained normal. CT imaging revealed a thick-walled gallbladder filled with stones and positioned directly against the right rectus abdominis muscle. The muscle appeared heterogeneous and infiltrated. Between the gallbladder and the skin was a subcutaneous collection containing a calcified focus measuring approximately 32 by 21 millimeters. The finding suggested an abscess caused by a developing cholecystocutaneous fistula, with a gallstone migrating into the abdominal wall.

Surgeons drained the swelling and recovered blood-tinged fluid as well as a gallstone, providing direct evidence that the gallbladder had eroded toward the skin. Such fistulas are much more commonly associated with neglected gallstones or chronic cholecystitis than with cancer. In this patient, the process was probably driven by several forces acting together. Tumor infiltration can compromise blood vessels in the gallbladder wall, causing ischemia and tissue death. Chronic inflammation and obstruction can raise pressure inside the organ, while stones repeatedly scrape and irritate the lining. The combination can produce microscopic perforations, infection and gradual extension into neighboring tissues. As the gallbladder was already adherent to the abdominal wall, the path of least resistance led outward, eventually creating a channel through muscle and subcutaneous tissue.

A review accompanying the case found fewer than 10 well-documented reports of cholecystocutaneous fistula caused by gallbladder carcinoma. Most patients were older adults with advanced adenocarcinoma, local invasion, gallstones and poor prospects for surgery. In several cases, the fistula was already present when the cancer was diagnosed. The current patient appears unusual because the fistula formed after the initial operation and during palliative chemotherapy rather than being the presenting feature. Still, the complication should be interpreted as a sign of advanced disease, not necessarily as a direct toxic effect of chemotherapy. The tumor’s contact with the abdominal wall, combined with necrosis and chronic inflammation, likely created the conditions for the fistula.

The report underscores why a smooth bile-duct stricture should not automatically be considered harmless when it occurs alongside gallstones, jaundice and unexplained weight loss. CT and magnetic resonance imaging remain essential for staging, but their sensitivity can fall when tumors grow as diffuse infiltrations rather than discrete masses. High-resolution ultrasound and endoscopic ultrasound can sometimes reveal irregular thickening of the gallbladder wall, invasion around the ducts or suspicious lymph nodes that are less apparent on routine scans. Repeated imaging, tissue sampling when feasible and close multidisciplinary review may be warranted when symptoms and imaging do not align. Once fistulization occurs in an unresectable tumor, care focuses on drainage, infection control, pain relief, nutritional support and maintaining biliary drainage, with chemotherapy offered when the patient can tolerate it. The authors emphasize that earlier recognition of infiltrative gallbladder cancer may offer the best chance of preventing this dramatic complication.